New Computer Modelling could Boost Drug Discovery

Scientists from Queen's University Belfast have developed a computer-aided data tool that could improve treatment for a range of illnesses.

The computer modelling tool will predict novel sites of binding for potential drugs that are more selective, leading to more effective drug targeting, increasing therapeutic efficacy and reducing side effects.

The data tool or protocol will uncover a novel class of compounds - allosteric drugs in G protein-coupled receptors (GPCRs).

GPCRs are the largest membrane protein family that transduce a signal inside cells from hormones, neurotransmitters, and other endogenous molecules. As a result of their broad influence on human physiology, GPCRs are drug targets in many therapeutic areas such as inflammation, infertility, metabolic and neurological disorders, viral infections and cancer. Currently over a third of drugs act via GPCRs. Despite the substantial therapeutic success, the discovery of GPCR drugs is challenging due to promiscuous binding and subsequent side effects.

Recent studies point to the existence of other binding sites, called allosteric sites that drugs can bind to and provide several therapeutic benefits. However, the discovery of allosteric sites and drugs has been mostly serendipitous. Recent X-ray crystallography, that determines the atomic and molecular structure, and cryo-electron microscopy that offers 3D models of several GPCRs offer opportunities to develop computer-aided methodologies to search for allosteric sites.

The researchers developed a computer-aided protocol to map allosteric sites in GPCRs with a view to start rational search of allosteric drugs, presenting the opportunity for new solutions and therapies for a range of diseases.

Dr Irina Tikhonova from the School of Pharmacy at Queen’s University and senior author, explains: “We have developed a novel, cost-effective and rapid pipeline for the discovery of GPCRs allosteric sites, which overcomes the limitations of current computational protocols such as membrane distortion and non-specific binding.

"Our pipeline can identify allosteric sites in a short time, which makes it suitable for industry settings. As such, our pipeline is a feasible solution to initiate structure-based search of allosteric drugs for any membrane-bound drug targets that have an impact on cancer, inflammation, and CNS diseases."

This research published in ACS Central Science is a collaboration with Queen's University Belfast and Queen Mary University of London. It is supported by the European Union ’s Horizon 2020 research and innovation programme under the Marie-Sklodowska-Curie grants agreement and Biotechnology and Biological Science Research Council.

Antonella Ciancetta, Amandeep Kaur Gill, Tianyi Ding, Dmitry S Karlov, George Chalhoub, Peter J McCormick, Irina G Tikhonova.
Probe Confined Dynamic Mapping for G Protein-Coupled Receptor Allosteric Site Prediction.
ACS Cent. Sci. 2021. doi: 10.1021/acscentsci.1c00802

Most Popular Now

AI Distinguishes Glioblastoma from Look-…

A Harvard Medical School–led research team has developed an AI tool that can reliably tell apart two look-alike cancers found in the brain but with different origins, behaviors, and treatments. The...

Overcoming the AI Applicability Crisis a…

Opinion Article by Harry Lykostratis, Chief Executive, Open Medical. The government’s 10 Year Health Plan makes a lot of the potential of AI-software to support clinical decision making, improve productivity, and...

Smart Device Uses AI and Bioelectronics …

As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called "a-Heal," designed by engineers at the University...

Dartford and Gravesham Implements Clinis…

Dartford and Gravesham NHS Trust has taken a significant step towards a more digital future by rolling out electronic test ordering using Clinisys ICE. The trust deployed the order communications...

AI Body Composition Measurements can Pre…

Adiposity - or the accumulation of excess fat in the body - is a known driver of cardiometabolic diseases such as heart disease, stroke, type 2 diabetes, and kidney disease...